Unique Ingredient Identifier 4550K0SC9B is listed as a ingredient substance
RN | 6131-90-4 |
NCIT | C47720 |
RXCUI | 237108 |
PUBCHEM | 23665404 |
MF | C2H3O2.Na.3H2O |
INCHI KEY | AYRVGWHSXIMRAB-UHFFFAOYSA-M |
SMILES | O.O.O.[Na+].CC([O-])=O |
UNII 4550K0SC9B SODIUM ACETATE is commonly included in medications in the following forms.
Route | Dosage Form | Potency |
---|---|---|
AN,INFILTRATION | INJECTION | 0.38 % |
AURICULAR (OTIC) | SOLUTION | 0.075 % |
AURICULAR (OTIC) | SOLUTION, DROPS | 0.027 % |
AURICULAR (OTIC) | SUSPENSION | 0.042 % |
AURICULAR (OTIC) | SUSPENSION, LIQUID | 0.68 % |
EXTRACORPOREAL | SOLUTION | 0.18 % |
IM - IV | INJECTION | 0.97 % |
IM - IV - SC | INJECTION | 0.65 % |
IM - SC | INJECTION | 0.2 % |
INTERSTITIAL | INJECTION | NA |
INTRA-ARTICULAR | INJECTION | ADJPH |
INTRACAVITARY | INJECTION | NA |
INTRADERMAL | INJECTION | 0.16 % |
INTRALESIONAL | INJECTION | ADJPH |
INTRAMUSCULAR | INJECTION | 0.4 %W/V |
INTRAOCULAR | SOLUTION | 0.39 % |
INTRAPERITONEAL | INJECTION | NA |
INTRAPLEURAL | INJECTION | NA |
INTRASYNOVIAL | INJECTION | ADJPH |
INTRAVENOUS | INJECTABLE | 0.2 mg/1mL |
INTRAVENOUS | INJECTABLE | 0.2 % |
INTRAVENOUS | INJECTION | 20.4 % |
INTRAVENOUS | INJECTION | 1.64 MG/ML |
INTRAVENOUS | INJECTION, SOLUTION | 0.2 MG/1ML |
INTRAVENOUS | INJECTION, SOLUTION | 0.04 % |
INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 12.5 % |
INTRAVENOUS | SOLUTION | 0.2 mg/1mL |
INTRAVENOUS | SOLUTION | NA |
INTRAVENOUS | SOLUTION, INJECTION | 2 % |
INTRAVENOUS INFUSION | INJECTION, SOLUTION | 0.04 % |
INTRAVITREAL | SUSPENSION, INJECTION | 0.39 % |
IV - SC | INJECTION | 0.2 % |
IV - SC | LIQUID | 0.2 % |
IV(INFUSION) | INJECTABLE | 0.16 % |
IV(INFUSION) | INJECTION | 59.4 % |
IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 6.25 % |
IV(INFUSION) | SOLUTION, INJECTION | 0.68 % |
NASAL | SOLUTION | NA |
NERVE BLOCK | INJECTION | 0.38 % |
OPHTHALMIC | EMULSION | 0.05 % |
OPHTHALMIC | POWDER, FOR SOLUTION | 0.39 % |
OPHTHALMIC | SOLUTION | 1.25 % |
OPHTHALMIC | SOLUTION, DROPS | 1.28 % |
ORAL | CONCENTRATE | NA |
ORAL | POWDER, FOR SOLUTION | 99.3 MG/1GM |
ORAL | SOLUTION | 3400 MG/1000ML |
ORAL | SOLUTION, INJECTION | 1.36 MG/1.7ML |
ORAL | SOLUTION, SYRUP | 7.2 MG/5ML |
ORAL | SYRUP | 21.45 MG/5ML |
OTIC | SUSPENSION | 0.03 % |
PARENTERAL | INJECTABLE | 0.16 % |
PARENTERAL | INJECTION | 10.37 % |
PARENTERAL | POWDER, FOR INJECTION SOLUTION | 1.25 % |
PHOTOPHERESIS | SOLUTION | 0.18 % |
SOFT TISSUE | INJECTION | ADJPH |
SUBCUTANEOUS | INJECTABLE | 0.2 % |
SUBCUTANEOUS | INJECTION | 0.2 % |
SUBCUTANEOUS | LIQUID | 0.15 % |
SUBCUTANEOUS | SOLUTION | 0.023 % |
SUBCUTANEOUS | SOLUTION, INJECTION | 0.35 % |
SUBMUCOSAL | SOLUTION, INJECTION | 0.08 % |
TOPICAL | EMULSION, CREAM | NA |
TOPICAL | SOLUTION | 0.3 MG/1ML |